Literature DB >> 15637307

Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production.

John S Millar1, Cyrille Maugeais, Katsunori Ikewaki, Daniel M Kolansky, P Hugh R Barrett, Elaine C Budreck, Raymond C Boston, Norio Tada, Seibu Mochizuki, Joep C Defesche, James M Wilson, Daniel J Rader.   

Abstract

OBJECTIVE: We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans. METHODS AND
RESULTS: Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148+/-0.049 versus 0.499+/-0.099 pools x d(-1); P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97+/-10.51 versus 21.32+/-4.21 mg x kg(-1) x d(-1), respectively; P=0.02).
CONCLUSIONS: This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637307     DOI: 10.1161/01.ATV.0000155323.18856.a2

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  24 in total

1.  Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

Authors:  Michael E Lassman; Thomas McAvoy; Anita Y H Lee; Derek Chappell; Oitak Wong; Haihong Zhou; Gissette Reyes-Soffer; Henry N Ginsberg; John S Millar; Daniel J Rader; David E Gutstein; Omar Laterza
Journal:  Clin Chem       Date:  2014-04-21       Impact factor: 8.327

2.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

3.  Familial genetic risk factors in premature cardiovascular disease: a family study.

Authors:  Oguzhan Yucel; Oguz Karahan; Ali Zorlu; Sinasi Manduz
Journal:  Mol Biol Rep       Date:  2011-12-28       Impact factor: 2.316

Review 4.  The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management.

Authors:  Zahid Ahmad; Amit Khera
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

5.  Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids.

Authors:  Mirjana Pavlic; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

6.  Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB.

Authors:  Daniel A Blasiole; Angie T Oler; Alan D Attie
Journal:  J Biol Chem       Date:  2008-02-13       Impact factor: 5.157

7.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

8.  Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Authors:  Haihong Zhou; Jose Castro-Perez; Michael E Lassman; Tiffany Thomas; Wenyu Li; Theresa McLaughlin; Xie Dan; Patricia Jumes; John A Wagner; David E Gutstein; Brian K Hubbard; Daniel J Rader; John S Millar; Henry N Ginsberg; Gissette Reyes-Soffer; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  Rapid Commun Mass Spectrom       Date:  2013-06-30       Impact factor: 2.419

9.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.